SCHEMBL19212128

SCHEMBL19212128

CN1CCC(c2ccc(CCN)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LSS P48449 1/20 0.55
QDPR P09417 2/20 0.47
SIGMAR1 Q99720 3/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
CYP1A2 P05177 2/20 0.43
SPHK1 Q9NYA1 1/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14081034 0.89 LSS (0.51) LSSQDPRSIGMAR1CYP1A2SPHK1
SCHEMBL19993063 0.86 LSS (0.55) LSSQDPRSIGMAR1CYP1A2MEN1
SCHEMBL2426347 0.86 LSS (0.58) LSSQDPRHDAC3HDAC4HDAC1
SCHEMBL14452295 0.83 SPHK1 (0.51) CYP1A2SPHK1CYP2C19KMT2ATAAR1
SCHEMBL15498535 0.83 LSS (0.55) LSSQDPRSIGMAR1CYP1A2SPHK1
SCHEMBL26520895 0.81 LSS (0.54) LSSQDPRSIGMAR1CYP1A2MEN1
SCHEMBL10264241 0.80 LSS (0.59) LSSQDPRDRD2
SCHEMBL20630095 0.80 LSS (0.52) LSSQDPRSIGMAR1CYP1A2SPHK1
SCHEMBL3948975 0.80 BACE1 (0.49) CYP1A2SPHK1CYP2C19KMT2ATAAR1
SCHEMBL158531 0.80 QDPR (0.55) LSSQDPRHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109071560-B Thienopyridine carboxamides as ubiquitin-specific protease inhibitors 瓦洛健康公司 2022-01-14 CN disclosed
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-02-09 US disclosed
EP-3414252-A1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Forma Therapeutics, Inc. (US) 2018-12-19 EP disclosed
WO-2017139778-A1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2017-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 LSS 4675/4885QDPR 1057/4885SIGMAR1 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.